Merrill maintains Onyx at neutral

Onyxx Pharmaceuticals Inc. kept its neutral rating by Merrill Lynch analyst Eric Ende on reports that the pricing for kidney drugs Sutent and Nexavar is nearly equal. Merrill had assumed a pricing advantage for Sutent. The analyst looks for survival data for Sutent in renal cancer possibly this year. Shares of the Emeryville, Calif., biopharmaceutical company were down 57 cents, or 2.03%, at $27.52 on volume of 952,548 shares versus the three-month running average of 1,121,920 shares. (Nasdaq: ONXX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.